Analyst ratings and price target adjustments are significant indicators for investors, often leading to stock price movements. JP Morgan's decision to maintain an Overweight rating and raise the price target for ResMed suggests a bullish outlook on the company's performance, which is likely to encourage investor confidence and could result in a short-term increase in the stock price.